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Abstract
Objectives: We examined whether plasma concentrations of amyloid beta (Ab) as protein derivatives play a
central role in the etiology of autistic features.
Design and Methods: Concentrations of human Ab (1-42), Ab (1-40), and Ab (40/42) in the plasma of 52 autistic
children (aged 3-16 years) and 36 age-matched control subjects were determined by using the ELISA technique
and were compared.
Results: Compared to control subjects, autistic children exhibited significantly lower concentrations of both Ab (1-
40) and Ab (1-42) and lower Ab (40/42) concentration ratio. Receiver operating characteristics curve (ROC) analysis
showed that these measurements of Ab peptides showed high specificity and sensitivity in distinguishing autistic
children from control subjects.
Conclusions: Lower concentrations of Ab (1-42) and Ab (1-40) were attributed to loss of Ab equilibrium between
the brain and blood, an imbalance that may lead to failure to draw Ab from the brain and/or impairment of b-
and g- secretase’s concentration or kinetics as enzymes involving in Ab production.
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1. Introduction
Autism and other related autism spectrum disorders
(ASDs) are behavioral syndromes that include various
degrees of verbal, nonverbal, and social impairment, as
well as restricted or stereotyped interests and activities.
The disorders are characterized by early onset (before
36 months of age) [1,2] and by long-lasting social or
cognitive handicaps. With an overall prevalence of
approximately 0.6% [3], ASDs are an important public
health problem worldwide. Although international con-
sensus considers these syndromes to be phenotypic
expressions of impairments affecting the development of
the central nervous system (CNS), numerous questions
concerning their etiopathology are still unanswered.
Children with autism generally find it difficult to
ignore irrelevant information and are easily distracted by
other stimuli. Therefore, we can assume that these chil-
dren may have a selective attention deficit. In humans,
prenatal stress is linked to an increased vulnerability to
various psychosocial problems of childhood and adult-
hood. In children, stress is associated with cognitive,
behavioral, physical, and emotional problems [4-7], as
well as with autism [8-10].
Free radicals seem to be implicated in the onset of
autism. Reactive oxygen species (ROS), including super-
oxide (O2
-), hydroxyl (_OH), hydrogen peroxide (H2O2),
singlet oxygen (1O2), and nitric oxide (NO
_), are pro-
duced through physiologic and pathologic processes
[11]. ROS are scavenged by specific defense systems,
including antioxidant enzymes (superoxide dismutase
[SOD], catalase [CAT], glutathione peroxidase [GPx])
and nonenzymatic antioxidants such as glutathione
(GSH) and metallothioneins (MTs). Many autistic chil-
dren seem to share a chronic flaw in the defense sys-
tems against ROS. In studies of the RBC of autistic
children, Sogut et al. (2003) found higher concentrations
of NO_ and GPx [12], Zoroglu et al. (2004) reported
higher concentrations of NO_ and thiobarbituric acid-
reactive substances (TBARs) [13], Chauhan et al. (2004)
found a reduction in antioxidant proteins [14], and
Geier et al. (2009) and Al-Gadani et al. (2009) described
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a decrease in reduced GSH [15,16]. In autistic Saudi
children, overexpression of SOD, together with slightly
inhibited CAT activity, indicated that these children are
under H2O2 stress [16]. It is well known that glutamate
is inhibited by astrocytes in a concentration-dependent
manner. The inhibition of CAT clearly potentiated this
effect.
Alzheimer’s disease (AD), the primary dementing dis-
order of the elderly, affects more than four million per-
sons in the United States. Aging is the chief risk factor
for AD. Important pathological hallmarks of AD include
loss of synapses and the presence of senile plaques (SPs)
and neurofibrillary tangles (NFTs). SPs consist of a
highly dense core of Ab peptide, a peptide 39 to 43
amino acids in length (1-42) that is surrounded by dys-
trophic neurites [17]. Ab (1-40), which composes
approximately 90% of total secreted Ab, aggregates
much more slowly than Ab (1-42) [18]. Ab in amyloid
plaques consists mainly of the Ab (1-42) species,
whereas vascular amyloid is composed primarily of Ab
(1-40). The relatively high solubility of Ab (1-40) may
allow this species to diffuse for greater distances than
the less soluble Ab (1-42), thereby increasing its deposi-
tion around brain vessels [19].
A growing body of evidence indicates that Ab peptide
toxicity is mediated by free radical damage to cell mem-
branes [20-23]. The concept that Ab induces lipid peroxi-
dation is a key component of the Ab-associated free
radical model of neurodegeneration in AD [23,24]. Con-
sistent with a free radical process, Ab causes lipid peroxi-
dation in brain cell membranes, and this peroxidation is
inhibited by free radical antioxidants [21,23]. Giedraitis et
al. (2007), suggest that the normal equilibrium between
cerebrospinal fluid (CSF) and plasma Ab may be dis-
rupted in AD patients and may result in the initiation of
amyloid deposition in the brain [25].
The findings of in vitro studies of lipid peroxidation
induced by Ab (1-42) and postmortem studies of lipid
peroxidation (and its sequelae) in the AD brain, together
with the confirmed role of oxidative stress in the etiol-
ogy of autism [14-16], initiated our interest to study
plasma concentration of Ab peptide in autistic Saudi
children and age-matched control subjects in an attempt
to investigate the equilibrium status between the brain
and blood and to highlight other factors that might con-
tribute in the alteration of plasma Ab peptide concen-
tration. This comparison may help to clarify the
causative role of Ab peptide-induced oxidative stress in
the pathology of autism and the possibility to use both
as biomarkers of this disorder if they recorded remark-
able sensitivity and specificity upon performing receiver
operating characteristics statistical analysis. This could
help in the early diagnosis and intervention to control
the prevalence of this disease.
2. Materials and methods
2.1. Subjects and methods
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000).
Written informed consent was provided by the chil-
dren’s parents, and the children themselves assented to
participation if they were developmentally able to do so.
Subjects for this study were enrolled through the Aut-
ism Research and Treatment (ART) Center clinic,
whose sample population consists of children aged 3 to
16 years with a diagnosis of ASD. The diagnosis was
confirmed by using the Autism Diagnostic Interview-
Revised (ADI-R), the Autism Diagnostic Observation
Schedule (ADOS), and the Developmental, Dimensional
Diagnostic Interview (3DI). Of the 52 autistic children,
40 were nonverbal and 12 were verbal. The intelligence
quotient (IQ) of all autistic children was lower than 80.
All children had sporadic autism (simplex cases), and all
tested negative for the Fragile × syndrome. The control
subjects were recruited from the well-baby clinic at King
Khaled University Hospital; they also ranged in age from
3 to 16 years. Subjects were excluded from the study if
they had dysmorphic features, tuberous sclerosis, Angel-
man syndrome, or other serious neurological (e.g., sei-
zures), psychiatric (e.g., bipolar disorder), or medical (e.
g., endocrine, cardiovascular, pulmonary, liver, kidney)
conditions. All participants were screened via parental
interview for current and past physical illness.
2.2. Samples collection
After overnight fast, 10 ml blood samples were collected
from both groups in test tubes containing sodium
heparin as anticoagulant. Tubes were centrifuged at
3500 rpm at room temperature for 15 minutes, plasma
was obtained and deep freezed (at -80°C) until analysis
time.
2.3. Measurement of Ab (1-40) and Ab (1-42)
Plasma concentrations of Ab were measured by using the
human Ab (1-40) and Ab (1-42) TGC ELISA kit (The
Genetics Company, Schlieren, Switzerland) according to
the manufacturer’s instructions. Briefly, plasma samples
were 100 times diluted in assay buffer and processed
according to the manufacturer’s recommended protocols.
Samples and standards were incubated in capture wells
overnight at 8°C with antibodies specific for Ab (1-40) or
Ab (1-42). The capture antibody was 6E10 (Sigma, St
Louis, Missouri), and the detection antibody was a bio-
tin-labelled G2-10 (The Genetics Company, Schlieren,
Switzerland). The synthetic Ab (1-40) peptide (Bachem,
Bubendorf, Switzerland) was used as the standard. After
several rinses, the enzyme-conjugated detection reagent
was added to the wells for 30 minutes. After additional
rinses, wells were incubated with the chromogen solution
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for 30 minutes at room temperature, shielded from light.
After the addition of the stop solution, the wells were
read for absorption at 450 nm, and the Ab concentration
in the samples was calculated from standard curves. The
detection limit was 25 pg/mL.
2.4. Statistical analysis
Results were expressed as means ± S.D. Statistical com-
parisons were performed with independent t-tests with
the Statistical Package for the Social Sciences (SPSS).
Significance was assigned at the level of P < 0.05. Recei-
ver operating characteristics curve (ROC) analysis was
performed. Area under the curve, cutoff values, and
degree of specificity and sensitivity were calculated.
3. Results
Table 1 presents plasma concentrations of Ab (1-40),
Ab (1-42), and Ab (40/42) ratio. Compared to age-
matched control subjects, autistic children exhibited sig-
nificantly lower plasma concentrations of Ab (1-40) and
Ab (1-42) (P < 0.05) and non-significant lower Ab (40/
42) ratio (P = 0.168). Figure 1 illustrates the mean
values of the measured Ab peptides. The figures clearly
show that overlap in the distributed values around the
means of the autistic and control groups was seen in
the concentrations of Ab (1-40). This overlap could be
due to the fact that the individual data set within each
group was dispersed or spread out around the means.
Table 2 and Figure 2 show the Pearson correlations
between the three measured variables.
Table 3 and Figure 3 show the results of ROC analy-
sis: the area under the curve (AUC) and the specificity
and sensitivity of Ab (1-40), Ab (1-42), and Ab (40/42).
4. Discussion
In general, Ab (1-40) is less neurotoxic, less common in
the neuritic plaques of AD, and less likely to be involved
in the neuropathology of AD than Ab (1-42). However,
Ab (1-42) is more difficult to study than Ab (1-40)
because of polymerization. As is the case for any pep-
tide, the concentrations of Ab are a balance between its
rate of synthesis and its rate of degradation [26]. More-
over, it has been reported that the concentrations of Ab
in brain and blood are in equilibrium, through the
blood-brain-barrier (BBB), and that peripheral sequestra-
tion of Ab may shift this equilibrium toward the blood,
eventually drawing out the excess from the brain ("sink”
effect) [27].
In the present study, the concentrations of both Ab
(1-40) and Ab (1-42) were lower in autistic children
than in age-matched control subjects (Table 1 Figure 1).
This finding could be attributed to loss of Ab equili-
brium between the brain and blood, which may lead to
the failure to draw out Ab from the brain, i.e., increased
blood-to-brain influx and decreased brain-to-blood
efflux across the BBB. The observed low plasma concen-
trations of Ab (1-40) and (1-42) in the autistic Saudi
children, together with the LPS hypothesis of Jaeger et
al. [28], could be easily supported by the findings of
many studies showing that children with autism have an
overload of gram-negative bacteria that contain LPS as a
causative agent of mitochondrial dysfunction, a bio-
chemical aspect recorded in a high percentage of autistic
patients [16,29-32].
Proteolytic cleavage of amyloid precursor protein
(APP) by the sequential actions of b- and g-secretases
form the neurotoxic Ab peptide, which typically consists
of 40 or 42 amino acid residues (the amyloidogenic
pathway). This could help to suggest the impairment of
b- and g- secretase’s levels and/or kinetics in autistic
patients showing lower plasma concentrations of Ab (1-
40) and Ab (1-42). This suggestion could be supported
by the work of Sokol et al. [33] and Bailey et al. [34],
who reported higher plasma concentrations of secreted
APPa in autistic patients than in aged-matched control
subjects and their recommendation to measure sAPP-a
concentrations in serum and human umbilical cord
blood as a potential tool for the early diagnosis of
autism.
The pathogenesis of many neurological disorders is
also believed to be associated with oxidative stress,
which may be responsible for the dysfunction or death
of neurons. Ab can serve as a metalloenzyme to cata-
lyze the generation of neurotoxic H2O2 from O2
through binding and reduction of Cu (II) [35]. Fang et
al. (2010) reported that oligomer and the fibril form of
Ab (1-42) can promote the generation of H2O2 when
the concentration of co-incubated Cu (II) is below a
critical level [36] and the amount of TBARS reactivity
is greatest when generated by Ab (1-42) ˃˃ Ab (1-40)
[37].
Table 1 Mean ± S.D of plasma levels of Ab (1-40), Ab
(1-42) and Ab (40/42) ratio in autistic patients (N = 52)
compared to age- matching controls (N = 36).
Parameter Group N Minimum Maximum Mean ± S.D P
value
Ab (1-40) Control 36 96.45 285.97 185.43 ±
48.76
0.000
Autistic 52 84.03 217.1 145.07 ±
28.72
Ab (1-42) Control 36 55.38 76.54 64.72 ± 5.67 0.000
Autistic 51 42.12 79.62 54.86 ± 6.16
Ab (40/42) Control 36 1.59 4.39 2.86 ± 0.71 0.168
Autistic 50 1.41 4.29 2.67 ± 0.58
This table describes the independent t-test between the control and autistic
groups regarding levels of Ab (1-40) andAb (1-42) expressed as pg/mL plasma
and Ab (40/42) ratio. Significant level at p < 0.05.
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At normal physiological conditions, SOD1 is known to
increase cellular resistance to oxidative stress [38]. How-
ever, when the SOD enzyme is overexpressed at levels
that are much higher than those of other antioxidant
enzymes, such as GPx and CAT, or higher than the abil-
ity of cells to supply reducing equivalents, increased oxi-
dative stress is observed [39]. Oxidative damage is likely
because of the generation of ˑOH from the interaction
of accumulating H2O2 with redox cycling proteins via
Fenton-like chemistry [40]. The lower Ab (1-42) and Ab
(1-40) plasma concentrations reported in the present
study, together with the proposed higher brain concen-
trations of both peptides, could be easily related to the
findings of previous reports by Al-Gadani et al. (2009),
which demonstrated that autistic Saudi children are
under H2O2 stress because of overexpression of SOD
and normal CAT activity [16].
Recent evidence suggests that the low-density lipopro-
tein receptor-related protein 1 (LRP1) transcytoses Ab
out of the brain across the blood-brain barrier (BBB)
[41]. Deane et al. [42] reported that in RAP knockout
mice the expression of LRP-1 is reduced in the brain
and that Ab (1-40) elimination from the brain to blood
is also reduced. These findings provide evidence for a
direct protein-protein interaction between LRP and Ab
and demonstrate that this interaction takes place in an
isoform-specific manner. This finding shows that Ab
isoforms are differentially transcytosed or endocytosed
through the BBB and that LRP at the BBB favors the
clearance of Ab isoforms relative to high b sheet
content.
Recently, Gu et al. [43] reported that exposure to lead
(Pb2+) increases the concentrations of Ab in the brain
and inhibits LRP1 expression; this finding could explain
the suggested Ab accumulation in the brains of the
autistic Saudi children in the present study. This expla-
nation could find support in the work of El-Ansary et
al. [31], who found that Pb2+ concentrations were signif-
icantly higher in the red blood cells (RBC) of 12 of 14
autistic Saudi children than in those of control subjects;
this finding indicates that autistic children are more vul-
nerable to Pb2+ toxicity and hence are more likely to
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                  Aβ (1-42) 
                     Aβ (40/42) 
Figure 1 Levels of the measured parameters in plasma. Mean of measured Aβ (1-40) (a), Aβ (1-42) (b), and Aβ (40/42) (c) in autistic patients
(N=52) compared to age- matching controls (N=36). Mean value for each group is designated by a line. Aβ level is expressed as pg/mL plasma.
Table 2 Pearson correlation test between the measured
amyloid beta peptides
Parameters R (Person Correlation) Sig.
Ab (1-40)~ Ab (1-42) 0.447 0.000 Pa
Ab (1-40)~ Ab (40/42) 0.859 0.000 Pa
a: Positive correlation
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accumulate Ab (1-40) and (1-42) in their brains. This
could be supported through considering the lower Ab
40/42 ratios recorded in the present study in autistic
patients compared to control subjects. It is well known
that clearance and transport from brain to blood is
facilitated by an increased Ab 40/42 ratio present at
young ages [44]. Moreover, young mouse model harbor-
ing a mutation favoring generation of Ab 1-42 over Ab
1-40 had a low Ab 40/42 ratio, was shifted to plaque
deposition [45].
Table 3 ROC analysis of the three measured amyloid beta peptides.
Parameter Area under the curve Best Cutoff value Sensitivity % Specificity %
Ab (1-40) 0.773 165.00 82.7% 75.0%
Ab (1-42) 0.905 60.29 82.4% 80.6%
Ab (40/42) 0.571 3.02 80.39% 38.89%
(a) 
(b) 
Figure 2 Pearson positive correlations between measured parameters with best fit line.
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Our speculated explanation could find a support in
the most recent experimental study of Frackowiak et al.
[46] in which they used immunoblotting to prove that
frozen autopsy brain samples of 9 autistic patients show
accumulation of Ab 40 and 42 in the cerebellum and
cortex. Moreover, the explained association between
chronic Pb toxicity previously recorded in 15/15 autistic
patients of Saudi Arabia and the speculated Ab accumu-
lation of the present study is in good agreement with
the finding of Garcidue˜nas [47,48] which show that
Children’s exposure to urban air pollution increases
their risk for auditory and vestibular impairment
through the accumulation of Ab 42 in their brainstems.
To better understand changes in Ab production, accu-
mulation, and clearance in autistic patients, it will be
necessary to continue studying the normal and disease-
related metabolism of Ab in various body fluids and in
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Figure 3 Receiver Operating Characteristics (ROC) analysis of the measured parameters in plasma of autistic patients. ROC curves
showing area under the curves, specificity and sensitivity of Aβ (1-42) (a), Aβ (1-40) (b) together with Aβ (40/42) (c).
Al- Ayadhi et al. Behavioral and Brain Functions 2012, 8:4
http://www.behavioralandbrainfunctions.com/content/8/1/4
Page 6 of 8
Nutrition plays a vital role in the methylation of DNA,
specifically the homocysteine (HCY)/S-adenosylmethio-
nine (SAM) cycle. This cycle requires the presence of
folate and B12, which facilitate the conversion of HCY to
methionine, which is then converted to SAM. SAM then
serves as a source of methyl groups for multiple methyla-
tion reactions, including the methylation of DNA. The
increased concentrations of Ab in the brains of autistic
Saudi children could be easily explained by the hypothesis
recently proposed by Lahiri and Maloney [49]. They pro-
posed that most AD cases follow an etiology based on
Latent Early-life Associated Regulation or “LEARn” as a
two-hit model [50,51]. They reported that exposure to
metals, nutritional imbalance (low B12), and other envir-
onmental stressors modify potential expression levels of
AD-associated genes (e.g., Ab peptide precursor protein)
in a latent fashion. Autistic patients are known to exhibit
oxidative stress [16], high RBC lead concentrations [31],
and impaired DNA methylation because of a remarkably
lower concentration of S-adenosylmethionine (SAM) [52].
On the basis of this information, the two-hit hypothesis of
Lahiri and Maloney [50] could explain the impaired Ab
concentrations in the plasma of autistic Saudi children, as
reported in the present study.
The Pearson correlations presented in Table 2 and Fig-
ure 2 show that while there was only an acceptable level
of correlation between Ab (1-40) and Ab (1-42) (correla-
tion coefficient less than 0.5), a very good level of associa-
tion was found between Ab (1-40) and Ab (40/42) ratio
(correlation coefficient of 0.859). This could be helpful to
suggest that lower values of Ab (1-40) and Ab (40/42)
ratio must be recorded together as biomarker in a patient
diagnosed as autistic while an association between Ab (1-
40) and Ab (1-42) is not a must.
Table 3 and Figure 3 illustrate the results of ROC ana-
lyses of the two measured Ab peptides. Although Ab
40/42 ratio reported low value of sensitivity and specifi-
city, absolute values of Ab (1-42) and Ab (1-40)
reported satisfactory figures of sensitivity and specificity
to be considered as potential biomarkers for autism.
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